Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Hypertension (Dallas, Tex. : 1979)|March 1, 1984
Role of endothelium in conversion of angiotensin I to angiotensin II in rabbit aortaJ A Saye, H A Singer, M J PeachBlood Vessels|January 1, 1984
Effects of cytochrome P-450 inhibitors on endothelium-dependent relaxation in rabbit aortaH A Singer, J A Saye, M J PeachThe American Journal of Physiology|June 1, 1993
Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytesJ A Saye, N V Ragsdale, R M Carey, et al.The American Journal of Physiology|February 1, 1989
Angiotensinogen gene expression in 3T3-L1 cellsJ A Saye, L A Cassis, T W Sturgill, et al.The Journal of Pharmacology and Experimental Therapeutics|May 15, 1998
Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdineR Zaczek, R J Chorvat, J A Saye, et al.Journal of Medicinal Chemistry|February 12, 2000
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonistL He, P J Gilligan, R Zaczek, et al.Bioorganic & Medicinal Chemistry|September 1, 2000
The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonistP J Gilligan, C Baldauf, A Cocuzza, et al.Antimicrobial Agents and Chemotherapy|December 3, 1999
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1J W Corbett, S S Ko, J D Rodgers, et al.Pageof 1